In mouse models, cucumarioside A2-2 (5 mg/kg i.p.)reduces tumor volume in prostate cancer xenografts by 45% within 14 days, accompanied by increased infiltration of M1 macrophages and CD8+ T cells [25]. This evidence concerns the gene CD8A and neoplasm.